Katy Mead
About Katy Mead
Katy Mead serves as the Associate Director of CMC Operations and Program Management at ElevateBio, where she has worked since 2023. With over six years of experience in early-phase clinical environments, she has a strong background in engineering and project management across various biotechnology companies.
Work at ElevateBio
Katy Mead currently serves as the Associate Director of CMC Operations and Program Management at ElevateBio, a position she has held since 2023. In this role, she is responsible for overseeing the operations related to Chemistry, Manufacturing, and Controls (CMC), ensuring that projects meet regulatory and operational standards. Prior to this role, she worked at ElevateBio as a Senior Process Engineer from 2019 to 2021 and as a Principal Process Engineer from 2021 to 2023, contributing to the development and optimization of manufacturing processes.
Education and Expertise
Katy Mead earned her Master of Science (MS) in Engineering Management from Tufts University, where she studied from 2016 to 2018. She also holds a Bachelor of Science (B.S.) in Chemical and Biological Engineering from the University of Colorado Boulder, completed between 2009 and 2013. Her educational background provides a strong foundation for her expertise in process engineering and program management within the biotechnology sector.
Background
Before joining ElevateBio, Katy Mead gained valuable experience in various engineering roles. She worked at WAVE Life Sciences Ltd. as a Process Engineer I and II from 2017 to 2019, where she focused on process development. Additionally, she held positions at DPS Engineering and Hyde Engineering + Consulting as a CQV Engineer, contributing to quality control and validation processes. Her early career included a research internship at Targeted Growth in 2010 and a role as a PREP Scholar at NIST from 2011 to 2013.
Achievements
Katy Mead has a proven track record of leading complex cross-functional projects aimed at achieving operational readiness and enabling manufacturing. Her extensive experience spans over six years in early-phase clinical environments, where she has interfaced with both internal and external manufacturing functions. She possesses firsthand experience with various modalities, including viral vectors, oligonucleotides, cell gene therapies, and biologics, which enhances her capability in the biotechnology field.